Left vs Right Side of Colon Cancer Has Prognostic Value
The occurrence of colon cancer on the right vs left side of the colon is a prognostic factor for all stages of the disease.
Peritoneal Involvement Shortened Survival in Metastatic CRC
Patients with peritoneal metastatic colorectal cancer had significantly shorter overall survival compared with patients with other isolated sites of metastases.
Insurance Expansion Improved Care for Colorectal Cancer
The expansion of healthcare in Massachusetts in 2006 was associated with increased rates of resection for patients with colorectal cancer.
Benefits of Colon Cancer Screening Decrease After Age 75
Colonoscopy screening is modestly effective for preventing colorectal cancer in patients aged 70 to 74, but the benefits may begin to diminish after that.
Common Mutations May Lead to Worse CRC Outcomes in African-Americans
A set of genes that are more likely to be mutated in African-Americans vs Caucasians with colorectal cancer appears to increase the risk of metastases and relapse in mutant versions.
Could Gene Assay Help Guide Stage II Colon Cancer Treatment?
In this interview we discuss the GeneFx Colon test (or the ColDx assay), which can helpful identify patients with low- or high-risk stage II colon cancer.
ColDx Assay May Help Refine Prognosis in Stage II Colon Cancer
A gene expression microarray-based assay was able to successfully identify patients with stage II colon cancer who are at high risk for recurrence.
Location of Primary Tumor Matters in Colorectal Cancer
A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.
ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic Cancer
The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.
Meat, Alcohol, and Obesity Raise Stomach Cancer Risk
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara examines a recent report that warns of different factors associated with an increased risk of stomach cancer.
PD-1 Inhibitor Yields Responses in Hepatocellular Carcinoma
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.